Indication

Systemic sclerosis-associated interstitial lung disease

Systemic sclerosis-associated interstitial lung disease is a severe pulmonary manifestation and the leading cause of mortality in patients diagnosed with systemic sclerosis, an autoimmune connective tissue disorder. Read more about Systemic sclerosis-associated interstitial lung disease

14 drugs 13 manufacturers

Advertisement

Drugs that treat it

Common Systemic sclerosis-associated interstitial lung disease therapies.

Showing 1–9 of 14 drugs

ACTEMRA (tocilizumab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+4
GENENTECH

OFEV (nintedanib esylate)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
Boehringer Ingelheim

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
DR.REDDY'S LAB

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
APOTEX CORP

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
CIPLA USA, INC.

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
EDENBRIDGE/DEXC

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
SANDOZ

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
GSMS, INC.
Filter & compare in the drug finder →Opens the drug finder with Systemic sclerosis-associated interstitial lung disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Systemic sclerosis-associated interstitial lung disease.

Systemic sclerosis-associated interstitial lung disease is a severe pulmonary manifestation and the leading cause of mortality in patients diagnosed with systemic sclerosis, an autoimmune connective tissue disorder.

The condition primarily impacts the respiratory system and is characterized pathophysiologically by autoimmune-mediated inflammation, microvascular injury, and progressive extracellular matrix deposition leading to pulmonary fibrosis.

Clinically, affected individuals experience exertional dyspnea, nonproductive cough, and restrictive lung impairment on pulmonary function testing.

High-resolution computed tomography typically demonstrates bilateral reticular opacities and ground-glass changes, predominantly manifesting as a nonspecific interstitial pneumonia pattern, which may progress to irreversible fibrosis and respiratory failure.

Personalize your experience

Follow Systemic sclerosis-associated interstitial lung disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it